ArticleJournal of diabetes and metabolic disorders2024
Circulating mannose-binding lectin in diabetic patients and risk of vascular complications: a systematic review and meta-analysis.
Article in Journal of diabetes and metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Recent studies have confirmed the involvement of mannose-binding lectin (MBL) in the pathogenesis of vascular complications in individuals with diabetes. Due to the discrepancy between the results of studies, a meta-analysis was conducted to evaluate MBL levels in patients with diabetes and its vascular complications. Methods: We reviewed all observational studies published in PubMed/Medline, Scopus, EMBASE, and Web of Science Core Collection databases to identify relevant studies up to 1 April 2024. To account for describing heterogeneity among the studies, I Results: Twenty-eight papers were encompassed in this meta-analysis. The mean difference in MBL levels between patients with diabetic nephropathy and diabetic retinopathy differed significantly compared with the healthy control group and the diabetic group without vascular complications (P-value < 0.05). Moreover, the pooled results revealed a significant relationship between MBL levels and the incidence of vascular complications (pooled HR = 1.44, 95% CI: 1.07-1.95, P-value < 0.05) and disease-related mortality (pooled HR = 1.52, 95% CI: 1.07-2.16, P-value < 0.05) among diabetic patients. Also, there was a direct association between incidence of nephropathy in diabetics and higher levels of MBL (pooled HR = 2.16, 95% CI: 1.52-3.08, P-value < 0.05). Conclusion: Diabetic patients with elevated MBL levels are potentially at increased risk of vascular complications such as nephropathy and retinopathy. Therefore, by determining MBL status in diabetic patients, it is possible to predict the progress and possible consequences of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.